BCM
RANI icon

Bridgeway Capital Management’s Rani Therapeutics RANI Stock Holding History

Bridgeway Capital Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.1K Hold
114,500
– – ﹤0.01% 1141
2025
Q4 		$155K Buy
+114,500
New +$173K ﹤0.01% 1061
2025
Q3 		– Sell
-46,500
Closed -$23.9K – 1266
2025
Q2 		$23.9K Hold
46,500
– – ﹤0.01% 1157
2025
Q1 		$58.6K Sell
46,500
-10,000
-18% -$14.8K ﹤0.01% 1111
2024
Q4 		$77.4K Sell
56,500
-15,000
-21% -$31.5K ﹤0.01% 1137
2024
Q3 		$154K Hold
71,500
– – ﹤0.01% 1107
2024
Q2 		$272K Buy
71,500
+20,000
+39% +$104K 0.01% 987
2024
Q1 		$160K Hold
51,500
– – ﹤0.01% 1141
2023
Q4 		$171K Hold
51,500
– – ﹤0.01% 1167
2023
Q3 		$112K Buy
+51,500
New +$197K ﹤0.01% 1206

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Bridgeway Capital Management's RANI Position: Q1 2026 in Review

Bridgeway Capital Management held its Rani Therapeutics (RANI) position steady in Q1 2026 at 114,500 shares worth $84.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1141.

Bridgeway Capital Management first reported a position in RANI in Q3 2023 and has held it in 10 quarters since. The position peaked at $272K in Q2 2024. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Bridgeway Capital Management held 114,500 shares of Rani Therapeutics worth $84.1K as of Q1 2026.
  • Bridgeway Capital Management left its Rani Therapeutics share count unchanged in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1141 holding.
  • Bridgeway Capital Management first reported a position in Rani Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • Bridgeway Capital Management's Rani Therapeutics position peaked at $272K in Q2 2024.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.